Novartis’ Ilaris Earns FDA Approval for Rare Autoinflammatory Disease

Novartis’ Ilaris (canakinumab) has received FDA approval for treatment of active Still’s disease, including adult-onset Still’s disease (AOSD).

The anti-inflammatory drug is the first approved treatment for AOSD, a rare type of inflammatory arthritis that features fevers, rash and joint pain.

Ilaris had received a priority review from the agency. The drug was previously approved for treatment of systemic juvenile idiopathic arthritis in patients aged 2 years and older.